Pediatric Nephrology at Fudan University Children's Hospital Shanghai | CMCS

Expert Kidney Disease Care for Children at China's Premier Children's Hospital

The Department of Nephrology at Fudan University Children's Hospital (FUCH) is one of China's most distinguished pediatric nephrology centers, with a national reputation for excellence in the diagnosis and management of nephrotic syndrome, glomerulonephritis, hereditary kidney diseases, acute kidney injury, chronic kidney disease, and pediatric dialysis and kidney transplantation. The department combines outstanding clinical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international families access to some of China's most eminent pediatric nephrologists and the latest evidence-based treatments for complex childhood kidney diseases.

For international families with a child with nephrotic syndrome, a hereditary kidney disease, a rare glomerular condition, or progressive chronic kidney disease — FUCH's nephrology department represents one of the most compelling destinations in Asia. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international families throughout their child's care journey at FUCH.

About the Department

FUCH's nephrology department is a national key clinical specialty operating dedicated pediatric nephrology inpatient wards, a comprehensive outpatient nephrology clinic, a pediatric dialysis unit (hemodialysis and peritoneal dialysis), a kidney biopsy service, a renal pathology laboratory, a hereditary kidney disease genetics clinic, and works in close collaboration with urology, transplant surgery, genetics, and immunology through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading pediatric nephrology journals including Journal of the American Society of Nephrology, Kidney International, Pediatric Nephrology, Clinical Journal of the American Society of Nephrology, and American Journal of Kidney Diseases.

Conditions Treated

Nephrotic Syndrome

• Idiopathic Nephrotic Syndrome (Minimal Change Disease) — Prednisolone induction; cyclophosphamide for frequently relapsing and steroid-dependent NS; levamisole for steroid-dependent NS; rituximab for steroid-dependent and frequently relapsing NS refractory to other agents
• Focal Segmental Glomerulosclerosis (FSGS) — Steroid therapy; calcineurin inhibitors (cyclosporine, tacrolimus); mycophenolate mofetil; sparsentan for primary FSGS; genetic testing for hereditary FSGS (NPHS1, NPHS2, WT1, TRPC6, INF2)
• Membranous Nephropathy — PLA2R antibody testing; rituximab for PLA2R-positive MN; calcineurin inhibitors; obinutuzumab for refractory MN
• Congenital Nephrotic Syndrome — NPHS1 (nephrin) and NPHS2 (podocin) mutations; albumin infusions; ACE inhibitors; indomethacin; bilateral nephrectomy and dialysis/transplantation for severe cases
• Steroid-Resistant Nephrotic Syndrome — Genetic panel testing; kidney biopsy; calcineurin inhibitors; rituximab; sparsentan

Glomerulonephritis

• IgA Nephropathy — ACE inhibitors/ARBs; corticosteroids for proteinuric IgAN; sparsentan; targeted-release budesonide (Nefecon); iptacopan for complement-mediated IgAN
• IgA Vasculitis Nephritis (Henoch-Schönlein Purpura Nephritis) — ACE inhibitors; corticosteroids for crescentic disease; mycophenolate mofetil
• Lupus Nephritis — Class III/IV: mycophenolate mofetil or cyclophosphamide + corticosteroids; belimumab; voclosporin; anifrolumab; maintenance therapy
• ANCA-Associated Vasculitis (AAV) — Rituximab + corticosteroids for induction; rituximab maintenance; avacopan for complement-mediated AAV
• Anti-GBM Disease (Goodpasture Syndrome) — Plasmapheresis + cyclophosphamide + corticosteroids
• C3 Glomerulopathy & Dense Deposit Disease — Complement pathway inhibitors; iptacopan; pegcetacoplan; eculizumab for C3G with complement dysregulation
• Membranoproliferative Glomerulonephritis (MPGN) — Underlying cause identification; complement inhibition for complement-mediated MPGN
• Post-Infectious Glomerulonephritis — Supportive care; antihypertensive therapy; antibiotic treatment of underlying infection

Hereditary Kidney Diseases

• Alport Syndrome — COL4A3/COL4A4/COL4A5 mutation testing; ACE inhibitors for proteinuria reduction; sparsentan; lademirsen (anti-miR-21) in clinical trials; kidney transplantation planning
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) — PKD1/PKD2 mutation testing; tolvaptan for rapidly progressive ADPKD; blood pressure control; pain management
• Autosomal Recessive PKD (ARPKD) — PKHD1 mutation testing; blood pressure control; management of congenital hepatic fibrosis; dialysis and transplantation planning
• Nephronophthisis — NPHP gene panel testing; supportive care; kidney transplantation
• Bardet-Biedl Syndrome — Genetic diagnosis; setmelanotide for obesity; multidisciplinary management
• Tuberous Sclerosis Complex (Renal) — Everolimus for renal angiomyolipomas; surveillance for renal cell carcinoma
• Von Hippel-Lindau Disease — Belzutifan for VHL-associated RCC and hemangioblastomas; surveillance
• Dent Disease & Lowe Syndrome — CLCN5 and OCRL mutation testing; citrate supplementation; ACE inhibitors
• Gitelman & Bartter Syndromes — Electrolyte replacement; indomethacin for Bartter syndrome
• Primary Hyperoxaluria — Lumasiran (RNAi therapy) for PH1; nedosiran for PH1 and PH2; combined liver-kidney transplantation for advanced disease
• Cystinosis — Cysteamine therapy; kidney transplantation; extra-renal manifestations management
• Fabry Disease (Renal) — Enzyme replacement therapy (agalsidase alfa/beta); migalastat for amenable mutations

Acute Kidney Injury (AKI)

• AKI in Critically Ill Children — Fluid management; renal replacement therapy (CRRT) for severe AKI; underlying cause treatment
• Hemolytic Uremic Syndrome (HUS) — STEC-HUS: supportive care; eculizumab for atypical HUS (aHUS); ravulizumab for aHUS; iptacopan for aHUS
• Thrombotic Thrombocytopenic Purpura (TTP) — Plasma exchange; caplacizumab; rituximab for immune TTP
• Contrast-Induced AKI — Prevention and management

Chronic Kidney Disease (CKD) & Renal Replacement Therapy

• CKD Management — Blood pressure control (ACE inhibitors, ARBs); proteinuria reduction; anemia management (ESAs, roxadustat); mineral bone disease (phosphate binders, active vitamin D, cinacalcet); growth hormone for CKD-associated growth failure; nutritional support
• Peritoneal Dialysis (PD) — Automated PD (APD) for children; PD catheter insertion; PD adequacy monitoring; peritonitis management
• Hemodialysis (HD) — Pediatric hemodialysis with child-appropriate equipment; vascular access management
• Kidney Transplantation — Pre-transplant evaluation and preparation; living and deceased donor transplantation coordination; immunosuppression management; rejection treatment; post-transplant monitoring

Hypertension & Tubular Disorders

• Pediatric Hypertension — Secondary hypertension workup; renovascular hypertension; antihypertensive therapy optimization
• Renal Tubular Acidosis (RTA) — Type 1, 2, and 4 RTA; alkali therapy; underlying cause identification
• Nephrocalcinosis & Nephrolithiasis — Metabolic evaluation; dietary modification; thiazide diuretics; citrate supplementation; urological intervention coordination

Hereditary Kidney Disease Genetics Program

FUCH's hereditary kidney disease genetics program is one of the most comprehensive in China for pediatric patients:

• Comprehensive Renal Gene Panel — NGS panel testing for 200+ genes associated with hereditary kidney diseases; whole exome sequencing for undiagnosed cases
• Genetic Counseling — Pre- and post-test counseling; family cascade testing; reproductive counseling
• Genotype-Phenotype Correlation — Mutation-guided prognosis and treatment selection (e.g., NPHS2 R229Q for FSGS; COL4A mutations for Alport syndrome)
• Novel Therapy Access — Lumasiran for PH1; sparsentan for FSGS and IgAN; iptacopan for complement-mediated kidney diseases

Why International Families Choose FUCH Nephrology

• Hereditary Kidney Disease Expertise — Comprehensive genetic panel testing and genotype-guided therapy for Alport syndrome, FSGS, PKD, and rare hereditary nephropathies
• Novel Therapy Access — Lumasiran, sparsentan, iptacopan, and other novel agents for rare kidney diseases
• Complement-Mediated Disease Expertise — Eculizumab, ravulizumab, and iptacopan for aHUS, C3G, and ANCA vasculitis
• Pediatric Dialysis & Transplantation — Comprehensive renal replacement therapy program including APD, HD, and kidney transplantation
• Rituximab for Nephrotic Syndrome — Extensive experience with rituximab for steroid-dependent and frequently relapsing NS
• Cost-Effectiveness — World-class pediatric nephrology care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your child's kidney disease history, urinalysis, kidney function tests, kidney biopsy reports, genetic testing results, and current medications with CMCS.
2. Medical Record Preparation — We translate and organize your child's records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate pediatric nephrologist based on your child's condition — nephrotic syndrome, glomerulonephritis, hereditary kidney disease, AKI, or CKD.
4. Priority Scheduling — We secure a consultation with minimal waiting time.
5. Travel & Logistics — Assistance with visa invitation letters, family accommodation near FUCH, and Shanghai airport transfers.
6. On-Site Concierge — Bilingual coordinators accompany your family throughout hospital visits, managing registration, translation, and communication.
7. Diagnostic Support — Full coordination of kidney biopsy, genetic panel testing, complement studies, and other required investigations.
8. Post-Consultation Follow-Up — Biopsy and genetic report translation, treatment plan interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If your child has nephrotic syndrome, a hereditary kidney disease, glomerulonephritis, chronic kidney disease, or a rare kidney condition — CMCS can arrange a specialist consultation with FUCH's pediatric nephrology team in Shanghai.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com